BioPharm International-10-04-2010

home / journals / biopharm-international / biopharm-international-supplements-10-02-2010
Site Logo

BioPharm International, October 2010 Supplement (PDF)

October 2nd 2010
ArticleIssue PDF

The Evolution of Vaccines

table2_t-690799-1408639063847.gif

Release and Stability Testing Programs for a Novel Virus-Like Particle Vaccine

Travis Sadowski;Steven Pincus;Sarathi Boddapati;Jingning Li
October 2nd 2010
ArticlePeer-Reviewed Research

Release testing involves both standard potency assays and unique assays (particle size, NA activity) developed to ensure the physical, chemical, and biological stability of this type of vaccine.

table2_t-690800-1408639059498.gif

Characterization of Aluminum Hydroxide Gel and Oil-in-Water Emulsion Formulations Containing CpG ODNs

Ryan C. Anderson;Thomas S. Vedvick;Timothy S. Dutill;James Chesko;Christopher B. Fox;Steven G. Reed
October 2nd 2010
ArticlePeer-Reviewed Research

Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).

onraedt-fig1_t-690798-1408639069152.jpg

Sterilizing Filtration of Adjuvanted Vaccines: Ensuring Successful Filter Qualification

Martha Folmsbee, PhD;Annelies Onraedt, PhD;Anil Kumar;Jerold M. Martin
October 2nd 2010
ArticlePeer-Reviewed Research

Filterability and bacterial retention must be verified very early in process development to ensure successful sterilizing filtration validation.

table2_t-690797-1408639073293.gif

An Alternative Platform for Rapid Production of Effective Subunit Vaccines

Judith A. Appleton;Donna Cassidy-Hanley;Ashot Papoyan;Lucille Gagliardo;Xujie Zhang;Theodore G. Clark;Jyothi Jayaram;Yelena Bisharyan;Paul Colussi
October 2nd 2010
ArticlePeer-Reviewed Research

Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).

© 2024 MJH Life Sciences

All rights reserved.